Kyverna Therapeutics (KYTX) Accumulated Depreciation (2023 - 2026)

Kyverna Therapeutics' Accumulated Depreciation history runs 4 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• Quarterly Accumulated Depreciation fell 1.55% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (down 1.55% YoY) and the FY2025 annual result came in at $3.8 million, up 2.12% from the prior year.
• Accumulated Depreciation was $3.9 million for Q1 2026 at Kyverna Therapeutics, up from $3.8 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $4.2 million in Q2 2025 and bottomed at $2.5 million in Q4 2023.
• A 4-year average of $3.5 million and a median of $3.6 million in 2024 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2024 — Accumulated Depreciation soared 47.59% — and 2026, when it decreased 1.55%.
• Kyverna Therapeutics' Accumulated Depreciation stood at $2.5 million in 2023, then soared by 47.59% to $3.7 million in 2024, then rose by 2.12% to $3.8 million in 2025, then increased by 3.28% to $3.9 million in 2026.
• Business Quant data shows KYTX's Accumulated Depreciation at $3.9 million in Q1 2026, $3.8 million in Q4 2025, and $3.6 million in Q3 2025.